Tagged with AZ

Brazil A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera after a failed merger attempt, and Quantoom, Univercells and Fiocruz’s RNA-based vaccine production collaboration.   MediPharm Labs Enters Landmark Commercial…

China A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma; Candid Therapeutics’ T-cell engager agreement with WuXi Biologics, and the DLL3-targeted antibody parternship between Innovent Biologics and Roche. AbbVie secures…

Saudi Arabia AstraZeneca has made remarkable progress over the past three years in Saudi Arabia, gaining significant leadership in therapeutic areas like oncology and respiratory care, and expansion into rare diseases. Sameh ElFangary, Country President of AstraZeneca GCC & Pakistan shares insights into the company’s strategy and strong alignment with Saudi Arabia’s…

Europe Jazz Pharmaceuticals is about to open a new chapter in its history. As long-standing CEO and co-founder Bruce Cozadd prepares to step down for retirement, the neuroscience and oncology-focused company begins its search for a new leader and gets ready to commercialize recently FDA-approved HER2-targeted bispecific antibody, Ziihera.    End…

LatAm A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4 million investment in Brazil, and SteinCares’ plasma derivatives deal with Biotest.   Record dengue outbreak in Americas kills 7,700 this…

Switzerland Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of patients in Switzerland, but the country’s status as a global biopharmaceutical R&D hub?   Major Challenges As outlined elsewhere in…

Switzerland Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational firms. Over 0.5 percent of the entire Swiss population (48,000 out of 8.8 million) work in the life sciences, 67…

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster, Enhertu, among them; the launch of Novo’s Wegovy in China; Eli Lilly’s obesity partnership with Hong Kong-listed Laekna; Merck’s cancer…

Switzerland Dennis Engelke, General Manager for Switzerland and Austria at Jazz Pharmaceuticals, discusses his career trajectory and the company’s growth in these markets. He highlights Jazz’s commitment to patient access and innovation, especially following the 2021 acquisition of GW Pharmaceuticals, which has enabled the company to enter the epilepsy space. Engelke…

China An overview of some of the top stories from China’s pharma industry, including the arrest of AstraZeneca China’s top executive; Pfizer’s USD 1 billion China investment; WuXi AppTec’s continuing revenue decline, and Aditum Bio and Leads Biolabs’ creation of autoimmune disease-focused Oblenio Bio. AstraZeneca’s China chief in custody, believes unrelated…

USA Naming a Chief Artificial Intelligence (AI) officer may not be an industry first, but Lilly’s recent creation of the role with the appointment of Thomas Fuchs confirms the solid commitment pharma has already made to introducing AI in processes that range from drug discovery to marketing.   AI Leaders Eli…

China A roundup of some of the top stories coming out of China’s pharma industry, including AstraZeneca’s USD 1.92 billion deal with CSPC; Bayer’s new Shanghai incubator; Genentech’s purchase of Regor Pharmaceuticals’ breast cancer portfolio; Shanghai Fosun Pharmaceutical’s African manufacturing expansion, and CanSino’s USD 17 million polio vaccine grant from the…